Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
Authors: Stephen B. Wilton, Matthew T. Bennett, Ratika Parkash, Katherine Kavanagh, E. Marc Jolicoeur, Frank Halperin, Umjeet Jolly, Peter Leong-Sit, Rozsa Sas, Derek S. Chew, Sarah Singh, Stephanie Frisbee, Robert MacLachlan, Jaimie Manlucu, Camille Galloway, Wei Qi, Nancy Hiltz, Brady Robinson, Sabrina Wall, Mary Radyk, Bernice Tsang, Lynn Nymann, Marc Deyell, Elisa Ramser, Evan Lockwood, Nicole Ell, Luc Harvey, Colette Seifer, Rebecca Fromm, Benoit Plourde, Marina Sanchez, Vincent Spagnoli, Isabelle Roy, Erick Schampaert, Chantale Mercure
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Persistently depressed left ventricular ejection fraction (LVEF) after myocardial infarction (MI) is associated with adverse prognosis and directs the use of evidence-based treatments to prevent sudden cardiac death and/or progressive heart failure. <h3>Objective</h3> To assess adherence with guideline-recommended LVEF reassessment and to study the evolution of LVEF over 6 months of follow-up. <h3>Design, Setting, and Participants</h3> This was a multicenter cohort study at Canadian academic and community hospitals with on-site cardiac catheterization services. Patients with type 1 acute MI and LVEF less than or equal to 45% during the index hospitalization were enrolled between January 2018 and August 2019 and were followed-up for 6 months. Data analysis was performed from May 2020 to September 2021. <h3>Exposures</h3> Baseline clinical factors, in-hospital care and LVEF, and site-specific features. <h3>Main Outcomes and Measures</h3> The main outcomes were receipt of repeat LVEF assessment by 6 months and the presence of a persistent LVEF reduction at 2 thresholds: LVEF less than or equal to 40%, prompting consideration of additional medical therapy for heart failure, or LVEF less than or equal to 35%, prompting referral for implanted cardioverter defibrillator in addition to medical therapy. <h3>Results</h3> This study included 501 patients (mean [SD] age, 63.3 [13.0] years; 113 women [22.6%]). Overall, 370 patients (73.4%) presented with STEMI, and 454 (90.6%) had in-hospital revascularization. The median (IQR) baseline LVEF was 40% (34%-43%). Of 458 patients (91.4%) who completed the 6-month follow-up, 303 (66.2%; 95% CI, 61.7%-70.5%) had LVEF reassessment, with a range of 46.7% to 90.0% across sites (χ<sup>2</sup><sub>13</sub> = 19.6;<i>P</i> = .11). Participants from community hospitals were more likely than those from academic hospitals to undergo LVEF reassessment (73.6% vs 63.2%; χ<sup>2</sup><sub>1</sub> = 4.50;<i>P</i> = .03), as were those with worse LVEF at baseline. Follow-up LVEF improved by an absolute median (IQR) of 8% (3%-15%). However, 103 patients (34.1%) met the definitions of clinically relevant LVEF reduction, including 52 patients (17.2%) with LVEF less than or equal to 35% and 51 patients (16.9%) with LVEF of 35.1% to 40.0%. <h3>Conclusions and Relevance</h3> In this cohort study, approximately 1 in 3 patients with at least mild LVEF reduction after acute MI did not undergo indicated LVEF reassessment within 6 months, suggesting that programs to improve the quality of post-MI care should include measures to ensure that indicated repeat cardiac imaging is performed. In those with follow-up imaging, clinically relevant persistent LVEF reduction was identified in more than one-third of patients.